{"classes":[{"categories":[{"measurements":[{"comment":"SD not calculable with 1 participant","groupId":"OG000","spread":"NA","value":"3.02"},{"groupId":"OG002","spread":"2.409","value":"3.60"},{"comment":"SD not calculable with 1 participant","groupId":"OG003","spread":"NA","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"NGS sensitivity level=10e-4"},{"categories":[{"measurements":[{"comment":"SD not calculable with 1 participant","groupId":"OG000","spread":"NA","value":"3.02"},{"groupId":"OG002","spread":"4.788","value":"5.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"NGS sensitivity level=10e-5"},{"categories":[{"measurements":[{"comment":"SD not calculable with 1 participant","groupId":"OG000","spread":"NA","value":"30.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"NGS sensitivity level=10e-6"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"0.230","value":"2.94"},{"groupId":"OG003","spread":"2.766","value":"4.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"NGF sensitivity level=10e-4"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"6.776","value":"6.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"NGF sensitivity level=10e-5"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"3.508","value":"12.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"NGF sensitivity level=10e-6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Time to MRD Negativity status in specific NGS and NGF sensitivity levels","dispersionType":"Standard Deviation","groups":[{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1\n\nPomalidomide:\n\n4 mg po daily (Days 1-21) of each 28-day cycle\n\nDexamethasone:\n\nWeeks without daratumumab dosing 40 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects 75 years old 20 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects \\> 75 years old","id":"OG000","title":"Cohort A-1"},{"description":"ND-Pd Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG001","title":"Cohort A-2"},{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG002","title":"Cohort B-1"},{"description":"D Monotherapy Regimen\n\nEach cycle is 28 days\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG003","title":"Cohort B-2"}],"paramType":"MEAN","populationDescription":"All Randomized MRD Evaluable Subjects Achieving MRD Negativity","reportingStatus":"POSTED","timeFrame":"approximately up to 4 years","title":"Time to MRD Negativity Status in the Nivolumab + Daratumumab Cohort","type":"SECONDARY","unitOfMeasure":"Months"}